On Thursday, 25 September 2025, leaders, policymakers, researchers, clinicians, and patient advocates gathered at the European Parliament in Brussels (and online) for the high-level event:
“Cardiovascular Prevention as the Cornerstone of a Competitive Europe – Scaling Up Lipid Screening to Secure Next Generations.”
Ten years ago, FH Europe Foundation held its first-ever high-level event on familial hypercholesterolaemia (FH) paediatric screening in the European Parliament. It was a pioneering milestone that put inherited lipid disorders firmly on the political agenda. A decade later, the urgency remains the same: we can no longer wait.
That is why this meeting was more than a Parliament event; it was call to action. It built on the foundation laid by the Prague Declaration on FH Paediatric Screening and the Brussels Declaration on Lp(a) Testing and Management. It was part of a movement that places inherited lipid conditions at the centre of cardiovascular prevention strategies, where they have always belonged.
The event was co-hosted by MEP Romana Jerković, Chair of the MEP Cardiovascular Health Group, and MEP Tomislav Sokol, Member of SANT Committee on Public Health—underlining strong political momentum to put early detection, screening, and personalised prevention at the heart of Europe’s health and competitiveness agenda.
At the centre of the programme were the FH Europe Foundation Ambassadors: Lena-Rosa Hanauer (Austria), Joanna Kacprzak (Poland), Aedan Kaal (Netherlands), and Teevi Poobus (Estonia), who shared their lived experiences and speak not only on behalf of themselves, but for millions of children, families and undiagnosed individuals across Europe.